Departments of Pathology , Women's Hospital of Nanjing Medical University, Nanjing Maternity and Child Health Care Hospital, Nanjing, China.
Department of Cervical Diseases, Women's Hospital of Nanjing Medical University, Nanjing Maternity and Child Health Care Hospital, Nanjing, China.
Cancer Biother Radiopharm. 2024 Aug;39(6):395-405. doi: 10.1089/cbr.2021.0227. Epub 2021 Nov 12.
MicroRNAs have been discovered to have the possibility to play a significant role in cancer development. While miR-141-5p has been found upregulated in various cancers, its functions in cervical cancer have rarely been reported. The expression level of miR-141-5p was assessed in cervical cancer tissues and cell lines by RT-qPCR. The function of miR-141-5p in C33A and HeLa cells was detected by CCK-8, and colony formation, wound-healing, transwell chamber, and flow cytometry assays. Dual luciferase reporter was carried out to identify the interaction between miR-141-5p and BTG antiproliferation factor 1 (). miR-141-5p was upregulated in cervical cancer and was negatively associated with the prognosis of patients with cervical cancer. Functional analyses demonstrated that silenced miR-141-5p expression inhibited the cell proliferation, migration, and invasion, and alleviated apoptosis of C33A and HeLa cells. In addition, miR-141-5p suppresses the activity of BTG1-3'-UTR. Rescue assays demonstrated that the cervical cancer progression is suppressed by miR-141-5p inhibitor and retrieved by sh-BTG1. The authors' findings reveal that miR-141-5p exerts its role through targeting BTG1 in cervical cancer progression, indicating that miR-141-5p may represent a promising target for the treatment of cervical cancer patients. The Clinical Trial Registration number: (2019-KY013).
微小 RNA 已被发现有可能在癌症发展中发挥重要作用。虽然 miR-141-5p 在各种癌症中被发现上调，但它在宫颈癌中的作用很少有报道。通过 RT-qPCR 评估了宫颈癌组织和细胞系中 miR-141-5p 的表达水平。通过 CCK-8 检测、集落形成、划痕愈合、transwell 室和流式细胞术检测 miR-141-5p 在 C33A 和 HeLa 细胞中的功能。双荧光素酶报告基因检测鉴定 miR-141-5p 与 BTG 增殖抑制因子 1 () 之间的相互作用。miR-141-5p 在宫颈癌中上调，与宫颈癌患者的预后呈负相关。功能分析表明，沉默 miR-141-5p 表达抑制了 C33A 和 HeLa 细胞的增殖、迁移和侵袭，并减轻了细胞凋亡。此外，miR-141-5p 抑制了 BTG1-3'-UTR 的活性。挽救实验表明，miR-141-5p 抑制剂抑制宫颈癌进展，而 sh-BTG1 则可恢复宫颈癌进展。作者的研究结果表明，miR-141-5p 通过靶向 BTG1 在宫颈癌进展中发挥作用，表明 miR-141-5p 可能成为治疗宫颈癌患者的有前途的靶点。临床试验注册号：(2019-KY013)。
